Literature DB >> 29714141

Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.

Xiang Chen1, Jilai Tian1,2,3, Gloria H Su4, Jiayuh Lin1.   

Abstract

BACKGROUND: Elevated production of the pro-inflammatory cytokine interleukin-6 (IL-6) and dysfunction of IL-6 signaling promotes tumorigenesis and are associated with poor survival outcomes in multiple cancer types. Recent studies showed that the IL-6/GP130/STAT3 signaling pathway plays a pivotal role in pancreatic cancer development and maintenance.
OBJECTIVE: We aim to develop effective treatments through inhibition of IL-6/GP130 signaling in pancreatic cancer.
METHODS: The effects on cell viability and cell proliferation were measured by MTT and BrdU assays, respectively. The effects on glycolysis was determined by cell-based assays to measure lactate levels. Protein expression changes were evaluated by western blotting and immunoprecipitation. siRNA transfection was used to knock down estrogen receptor α gene expression. Colony forming ability was determined by colony forming cell assay.
RESULTS: We demonstrated that IL-6 can induce pancreatic cancer cell viability/proliferation and glycolysis. We also showed that a repurposing FDA-approved drug bazedoxifene could inhibit the IL-6/IL-6R/GP130 complexes. Bazedoxifene also inhibited JAK1 binding to IL-6/IL-6R/GP130 complexes and STAT3 phosphorylation. In addition, bazedoxifene impeded IL-6 mediated cell viability/ proliferation and glycolysis in pancreatic cancer cells. Consistently, other IL-6/GP130 inhibitors SC144 and evista showed similar inhibition of IL-6 stimulated cell viability, cell proliferation and glycolysis. Furthermore, all three IL-6/GP130 inhibitors reduced the colony forming ability in pancreatic cancer cells.
CONCLUSION: Our findings demonstrated that IL-6 stimulates pancreatic cancer cell proliferation, survival and glycolysis, and supported persistent IL-6 signaling is a viable therapeutic target for pancreatic cancer using IL-6/GP130 inhibitors. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  IL-6/GP130 signaling; bazedoxifene; cell proliferation; cell viability; colony forming; glycolysis; pancreatic cancer.

Year:  2019        PMID: 29714141      PMCID: PMC7032663          DOI: 10.2174/1568009618666180430123939

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  50 in total

1.  Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels.

Authors:  Tomofumi Miura; Shuichi Mitsunaga; Masafumi Ikeda; Satoshi Shimizu; Izumi Ohno; Hideaki Takahashi; Junji Furuse; Masatoshi Inagaki; Sayumi Higashi; Hiroyuki Kato; Kimio Terao; Atsushi Ochiai
Journal:  Pancreas       Date:  2015-07       Impact factor: 3.327

Review 2.  The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.

Authors:  Christoph Garbers; Samadhi Aparicio-Siegmund; Stefan Rose-John
Journal:  Curr Opin Immunol       Date:  2015-03-06       Impact factor: 7.486

Review 3.  IL-6 as a keystone cytokine in health and disease.

Authors:  Christopher A Hunter; Simon A Jones
Journal:  Nat Immunol       Date:  2015-05       Impact factor: 25.606

4.  FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.

Authors:  Sing Yu Moorcraft; Khurum Khan; Clare Peckitt; David Watkins; Sheela Rao; David Cunningham; Ian Chau
Journal:  Clin Colorectal Cancer       Date:  2014-09-21       Impact factor: 4.481

5.  Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase.

Authors:  Andrew L Carey; Gregory R Steinberg; S Lance Macaulay; Walter G Thomas; Anna G Holmes; Georg Ramm; Oja Prelovsek; Cordula Hohnen-Behrens; Matthew J Watt; David E James; Bruce E Kemp; Bente K Pedersen; Mark A Febbraio
Journal:  Diabetes       Date:  2006-10       Impact factor: 9.461

6.  Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.

Authors:  Santiago Palacios; Tobie J de Villiers; Fiorenzo De Cicco Nardone; Amy B Levine; Robert Williams; Teresa Hines; Sebastian Mirkin; Arkadi A Chines
Journal:  Maturitas       Date:  2013-07-18       Impact factor: 4.342

Review 7.  The role of gp130 receptor cytokines in the regulation of metabolic homeostasis.

Authors:  Lena Cron; Tamara Allen; Mark A Febbraio
Journal:  J Exp Biol       Date:  2016-01       Impact factor: 3.312

8.  Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.

Authors:  David F Archer; JoAnn V Pinkerton; Wulf H Utian; José C Menegoci; Tobie J de Villiers; Chui Kin Yuen; Amy B Levine; Arkadi A Chines; Ginger D Constantine
Journal:  Menopause       Date:  2009 Nov-Dec       Impact factor: 2.953

Review 9.  Interleukin-6 and its receptor in cancer: implications for translational therapeutics.

Authors:  David S Hong; Laura S Angelo; Razelle Kurzrock
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

10.  Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy.

Authors:  Rashmi Bharti; Goutam Dey; Indranil Banerjee; Kaushik Kumar Dey; Sheetal Parida; B N Prashanth Kumar; Chandan Kanta Das; Ipsita Pal; Manabendra Mukherjee; Mridula Misra; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Paul B Fisher; Mahitosh Mandal
Journal:  Cancer Lett       Date:  2016-12-24       Impact factor: 8.679

View more
  6 in total

Review 1.  Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.

Authors:  Tomas Koltai; Stephan Joel Reshkin; Tiago M A Carvalho; Daria Di Molfetta; Maria Raffaella Greco; Khalid Omer Alfarouk; Rosa Angela Cardone
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

2.  Bazedoxifene Attenuates Abdominal Aortic Aneurysm Formation via Downregulation of Interleukin-6/Glycoprotein 130/Signal Transducer and Activator of Transcription 3 Signaling Pathway in Apolipoprotein E-Knockout Mice.

Authors:  Dan Yan; Haiyan Ma; Wei Shi; Pengcheng Luo; Tianshu Liu; Junyi Guo; Maocai Zhai; Jingwen Tao; Shengqi Huo; Chenglong Li; Jiayuh Lin; Sheng Li; Jiagao Lv; Cuntai Zhang; Li Lin
Journal:  Front Pharmacol       Date:  2020-04-17       Impact factor: 5.810

3.  Antitumor Effect and Immune Response of Nanosecond Pulsed Electric Fields in Pancreatic Cancer.

Authors:  Jing Zhao; Shuochun Chen; Lu Zhu; Liang Zhang; Jingqi Liu; Danxia Xu; Guo Tian; Tian'an Jiang
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244

4.  Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.

Authors:  Sarah Peisl; Claudia Mellenthin; Lucie Vignot; Carmen Gonelle-Gispert; Leo Bühler; Bernhard Egger
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

Review 5.  STAT3 signaling in ovarian cancer: a potential therapeutic target.

Authors:  Renba Liang; Xishan Chen; Li Chen; Fangzhu Wan; Kaihua Chen; Yongchu Sun; Xiaodong Zhu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

Review 6.  Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19.

Authors:  Jan Brábek; Milan Jakubek; Fréderic Vellieux; Jiří Novotný; Michal Kolář; Lukáš Lacina; Pavol Szabo; Karolína Strnadová; Daniel Rösel; Barbora Dvořánková; Karel Smetana
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.